Medicenna Therapeutics Investor Relations Material
Latest events
AGM 2024
Medicenna Therapeutics
Q3 2025
12 Feb, 2025
Q2 2025
14 Nov, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Medicenna Therapeutics Corp
Access all reports
Medicenna Therapeutics Corp. is a Canada-based clinical-stage biopharmaceutical company focused on the development of novel immunotherapies for cancer and other diseases. The company’s proprietary platforms are designed to create engineered cytokines, including interleukin-based therapies, aimed at enhancing immune system responses against tumors. The company is headquartered in Toronto, Canada, and its shares are listed on both the NASDAQ and the Toronto Stock Exchange.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
MDNA
Country
🇨🇦 Canada